SUMMARY The first long-term double-blind placebo controlled trial of high dose lecithin in senile dementia of the Alzheimer type is reported. Fifty one subjects were given 20-25 g/day of purified soya lecithin (containing 90% phosphatidyl plus lysophosphatidyl choline) for six months and followed up for at least a further six months. Plasma choline levels were monitored throughout the treatment period. There were no differences between the placebo group and the lecithin group but there was an improvement in a subgroup of relatively poor compliers. These were older and had intermediate levels of plasma choline. It is suggested that the effects of lecithin are complex but that there may be a "therapeutic window" for the effects of lecithin in the condition and that this may be more evident in older patients. 
Following the recognition of diminished levels of brain choline acetyltransferase in senile dementia of the Alzheimer type (SDAT) ' -clinical approaches based on the "cholinergic hypothesis"'2 have been developed. One The trial reported here has attempted to avoid these difficulties and was designed to test the hypothesis that high doses of lecithin might slow down the deterioration in relatively early cases of SDAT. To establish a differential rate of decline a double-blind placebo controlled design with rela-tively long treatment and follow-up periods was selected.
Materials and methods

Subjects
Potential subjects were obtained from various sources which included medical referrals to the hospital and other psychiatric services, direct referrals from the Alzheimer's Disease Society and a sample of elderly community residents (drawn from a large general practice or from residential homes) who were classified as possibly demented on the basis of their score on a brief screening questionnaire administered by a nurse.4" To be included, subjects had to fulfill several criteria.
(1) A 
Design
Subjects were allocated randomly to the lecithin or placeo group and monitored blindly during a 6 month period and reassessed following a 6 month drug-free period. The two groups were studied in parallel with no cross-over.
Preparations
Soya bean lecithin containing a minimum of 90% phosphatidyl plus lysophosphatidyl choline was supplied by Unilever Research Laboratories. This was prepared as a sweetened and flavoured emulsion in water, resembling a thick milk shake. The placebo consisted of a similar looking and tasting emulsion of "Flora" margarine to which propylgallate and ascorbic acid were added as antioxidants. 100 ml of suspension containing 25 g of lecithin was the dose selected and this was divided into two or three equal doses (depending on the subjects' choice) taken at mealtimes under the supervision of an informant.
Compliance was assessed throughout the study from informants' reports and by measuring the amount of preparation consumed. The overall measure of compliance was made at the end of the treatment period, subjects being classified as good compliers if they had taken consistently 75% or more of the dose prescribed, and as poor compliers if they took less than this.
Free plasma choline levels were determined at baseline and after 1, 2, 4 and 6 months of treatment. The estimation was carried out on a plasma ultrafiltrate using a radioenzymatic assay. 4445 Tests of orientation, learning and memory, perceptual and constructional skills and self care were administered. In view of the large number of tests used, it was determined that several hundred subjects would be required to analyse validly each test score as an individual dependent variable. Test scores were therefore reduced to three composite measures of different types of skill: orientation and verbal learning and memory (Factor 1) visuo-spatial and constructional skills (Factor 2) and self-care (Factor 3). These measures were derived by classifying tests according to content and extracting single measures of these by factor analysis (using IMAGE factoring).46 Factor 1 (FAC 1) was assessed at baseline and after 1, 2, 4 and 6 months on treatment and after 6 months follow-up. Factors 2 (FAC 2) and 3 (FAC 3) were assessed at baseline, after 6 months treatment and after 6 months follow-up. It should be pointed out that on FAC 1 and 3 the higher the score the higher the ability whereas on FAC 2 high scores indicate impairment (table 1) .
Statistcal treatment
Simple camparisons between groups for individual variables were made using univariate analysis of variance. Multivariate techniques were used to compare groups overall on several variables at baseline and to examine differences in the pattern of changes shown during the treatment When the two main groups (placebo and lecithin) were compared there were no significant differences on any of the three measures of change during treatment or follow-up. However in view of the relatively large number of poor compliers and the general impression that some subjects had responded better than others, a separate comparison of the good compliers, the poor compliers and the placebo group was carried out. Mean scores for these three groups on the three psychometric measures are shown in figs 3, 4 and 5.
Against expectations poor compliers appear to do best and improved during the treatment period on FAC 1 and FAC 3. Good compliers and placebo subjects show similar, slight changes during this period. The changes shown by poor compliers were compared with those shown by good compliers and by the placebo group.
For FAC 1 the overall mutlivariate comparisons of these changes did not quite reach acceptable levels of significance. However, for both comparisons the quadratic component of these changes was significant suggesting differences in the pattern of changes shown during treatment (table 4) .
From fig 3 it seems that whereas good compliers Step-down Test:
Changes: 
and placebo subjects showed slight fluctuations in performance during the 6 month treatment period the scores of poor compliers improved consistently during the first four months on lecithin but then fell to baseline levels at 6 months. For FAC 2 no group differences were significant. For FAC 3, the changes shown by good and poor compliers during treatment were significantly different (univariate F = 6-64; df. 1,20; p < 0 01) but the differences between poor compliers and palcebo subjects just failed to reach significance (univariate F = 3-80; df. 1,26; p < 0-06). Whereas good compliers and placebo subjects showed slight changes during the treatment period there was a marked improvement in the performance of poor compliers ( fig 5) .
Since there was a significant difference in age between good and poor compliers and between poor compliers and placebo, differences between the groups were re-examined using analysis of covariance to control for age. Similar results were found. However the analysis of trend for FAC I now failed to reach significance but significant group differences were found consistently for FAC 3 when comparing good with poor compliers (Univariate F = 7 70; df 1,18; p < 0-01) and poor compliers with placebo subjects (Univariate F = 4-64; df 1,24; p < 0.05).
Discussion
The effects of lecithin on psychometric test performance were complex and unpredicted. Thus, although as a whole there were no significant differences between the lecithin and placebo groups, when other factors such as compliance, plasma choline levels and age were taken into account interesting trends emerged. We had expected that good compliers would fare better. In fact the reverse was the case. In so far as a "responder" subgroup might be identified it was the relatively poor compliers who did best. They showed moderate improvement in FAC 1 (orientation, learning and memory) at four months, a time when their plasma choline level was just below twice the baseline value. This improvement was not maintained at six months by which time plasma choline had returned to baseline level. We suspect that this is because the patients had by then stopped taking any lecithin at all. The possibility that the drop in plasma choline in the poor-complier group might be due to enzyme induction cannot be excluded. A decline in plasma choline on an apparently fixed dose of lecithin has previously been reported47 but it should be noted that no such decline was found in the good complier group and the time course is probably inconsistent with the possibility of enzyme induction.
Little, Levy, Chuaqui-Kidd, Hand On FAC 3 (activities of daily living) there was a substantial improvement at six months and this was maintained after six months follow-up. Unfortunately since the assessments concerned were not carried out at four months no direct comparison with the transient improvements in memory and orientation can be carried out.
FAC 2 (visuo-spatial and constructional skills) showed a very slight decline in all three groups throughout the period of treatment and follow-up period.
A question then arises as to the comparability between the poor-compliers and the rest. It will be noted that they were older and that when the effects of age were controlled for the differences in FAC scores were no longer significant but those for FAC 3 became greater. 
